Silence Therapeutics (NASDAQ:SLN) Given New $25.00 Price Target at BMO Capital Markets
Silence Therapeutics (NASDAQ:SLN – Free Report) had its price objective reduced by BMO Capital Markets from $67.00 to $25.00 in a report issued on Tuesday,Benzinga reports. They currently have an outperform rating on the stock. Several other brokerages have also recently weighed in on SLN. Chardan Capital reissued a “buy” rating and set a $55.00 […]
Silence Therapeutics (NASDAQ:SLN – Free Report) had its price objective reduced by BMO Capital Markets from $67.00 to $25.00 in a report issued on Tuesday,Benzinga reports. They currently have an outperform rating on the stock. Several other brokerages have also recently weighed in on SLN. Chardan Capital reissued a “buy” rating and set a $55.00 […]
